For research use only. Not for therapeutic Use.
Ivosidenib（Cat No.:I007404）is a targeted therapy used to treat acute myeloid leukemia (AML) and cholangiocarcinoma with isocitrate dehydrogenase 1 (IDH1) mutations. By inhibiting the mutant IDH1 enzyme, Ivosidenib reduces the production of the oncometabolite 2-hydroxyglutarate, which promotes cancer cell growth and impairs cell differentiation. This action restores normal cell differentiation, slowing down tumor progression. Ivosidenib is particularly effective in patients with IDH1-mutant cancers, offering a precision medicine approach. Its targeted mechanism provides a well-tolerated treatment option, improving survival and quality of life in difficult-to-treat cancers.
| Catalog Number | I007404 |
| CAS Number | 1448347-49-6 |
| Synonyms | (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| Molecular Formula | C28H22ClF3N6O3 |
| Purity | 98% |
| Target | IDH1 |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | 12 nM (mouse IDH1R132H) |
| IUPAC Name | (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| InChI | InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1 |
| InChIKey | WIJZXSAJMHAVGX-DHLKQENFSA-N |
| SMILES | C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N |
| Reference | [1]. Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1Mutant Cancers. ACS Med Chem Lett. 2018 Jan 19;9(4):300-305. |
